Acibadem of Turkiye has signed a memorandum of understanding with Traverse Health, a real-world evidence provider and developer of cutting-edge digital solutions for healthcare industry, and joined the Traverse Health global proprietary network of partner hospitals. This MoU will develop ways for both parties to partner and explore patients' data and to power real-world evidence research in Turkiye.
Acibadem healthcare services ecosystem includes 22 hospitals and 18 medical centers in 5 countries and adopts a “360-degree” service approach in all aspects of healthcare.Traverse Health matches academic and sponsored trials with partner hospitals including multisite research projects while preserving patient privacy and following regulatory compliance (e.g., GDPR).
“This collaboration allows the mutual parties and pharmaceutical companies and medical device developers from around the world, to unlock the potential of region specific RWD, generate valuable insights about treatments and get scientifically validated answers to their research questions. In addition, it not only brings next generation trials to partner hospitals but enables its physicians and researchers an opportunity to offer innovative medical care to patients and to improve patients’ outcomes”, says Alex Loleit, CEO of Traverse Health.
“Acibadem has the responsibility to accelerate the introduction of innovative therapies to patients in Turkiye and nearby geographies, its involvement in partnerships will help researches and decision makers generate critical insights needed for development and bringing new drugs to the market as well as analyzing of treatment and diagnostic patterns will help to deliver efficacious treatments and procedures to our patients faster”, says Dr. Efe Onganer, Assistant Medical Director, Acibadem
Acibadem healthcare services ecosystem includes 22 hospitals and 18 medical centers in 5 countries and adopts a “360-degree” service approach in all aspects of healthcare.Traverse Health matches academic and sponsored trials with partner hospitals including multisite research projects while preserving patient privacy and following regulatory compliance (e.g., GDPR).
“This collaboration allows the mutual parties and pharmaceutical companies and medical device developers from around the world, to unlock the potential of region specific RWD, generate valuable insights about treatments and get scientifically validated answers to their research questions. In addition, it not only brings next generation trials to partner hospitals but enables its physicians and researchers an opportunity to offer innovative medical care to patients and to improve patients’ outcomes”, says Alex Loleit, CEO of Traverse Health.
“Acibadem has the responsibility to accelerate the introduction of innovative therapies to patients in Turkiye and nearby geographies, its involvement in partnerships will help researches and decision makers generate critical insights needed for development and bringing new drugs to the market as well as analyzing of treatment and diagnostic patterns will help to deliver efficacious treatments and procedures to our patients faster”, says Dr. Efe Onganer, Assistant Medical Director, Acibadem
